阿托伐他汀联合倍他乐克对冠心病合并短暂性脑缺血患者血清Hcy hs-CRP及血脂水平的影响

doi:10.3969/j.issn.1006-6233.2018.03.011

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1321 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the effects of atorvastatin and betaloc on serum Hcy, hs-CRP and blood lipid levels in patients with coronary heart disease complicated with transient ischemic attack. Methods: 80 patients with coronary heart disease complicated with transient ischemic attack admitted to our hospital from June 2015 to June 2017 were randomly divided into two groups, the control group received betaloc and the experimental group received atorvastatin. The electrocardiogram (ECG) improvement, the overall treatment effect of transient ischemic attack, disease-related parameters and adverse reactions were compared between the two groups. Results: The total effective rate of electrocardiogram improvement and the total effective rate of transient ischemic treatment in experimental group were significantly higher than those in control group (P <0.05); the thickness of intima-media, the maximum area of plaque transection, The levels of TG, TC, LDL-C, IL-8, HCY, Hs-CRP, NT-proBNP and FBG in the two groups were significantly lower than those in the control group (P <0.01). There was no significant difference (P> 0.05). Conclusion: Atorvastatin combined with betaloc has significant effect on serum Hcy, hs-CRP and serum lipid level in patients with coronary heart disease complicated with transient ischemia.

Key words： Atorvastatin Betaloc Coronary heart disease Transient ischemia

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Furong
	QI Ming
	et al

Cite this article:

ZHANG Furong,QI Ming,et al. Effect of Atorvastatin and Betaloc on Serum Hcy hs-CRP and Serum Lipids in Patients with Coronary Heart Disease Combined with Transient Ischemia[J]. HeBei Med, 2018, 24(3): 393-396.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.03.011 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I3/393

[1] Tikkanen M J, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels[J]. Int Cardiol,2013, 168(4): 3846~3852.
[2] 贾明,李春香.冠心病合并短暂性脑缺血发作治疗78例临床观察[J].陕西医学杂志.2011,40(3):376~377.
[3] Takagi H, Umemoto T. Reduction in coronary heart disease with atorvastatin independent of low-density lipoprotein cholesterol[J]. Int Cardiol,2011, 149(2): 267~269.
[4] 李明琰,崔永生,何文凯,等.冠心病患者经皮冠状动脉介入治疗术后规范药物治疗对颈动脉粥样硬化的影响[J].中国医科大学学报,2016,45(01):66~69.
[5] Haddas R, Lieberman I H, Block A. The relationship between fear-avoidance and objective biomechanical measures of function in patients with adult degenerative scoliosis[J]. Spine (Phila Pa 1976),2017.
[6] 段丽群,张文志.动态稳定非融合技术与后路固定融合技术治疗老年退变性脊柱侧弯的对比研究[J].临床骨科杂志,2013,16(3):320.
[7] Rosen J B, Ballantyne C M, Hsueh W A, et al. Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease Risk[J]. Lipids Health Dis,2015, 14: 103.
[8] 王力,张茁.缺血性脑卒中二级预防他汀类药物应用状况调查[J].中华老年心脑血管病杂志,2016,18(09):953~956.
[9] 严培玲,王菁,黄锡亮,等.匹伐他汀钙对颈动脉粥样硬化患者血脂和颈动脉斑块的影响[J].中国药物与临床,2015,15(6):864~865.
[10] 张铁须,谢鹏飞,田晓培.辛伐他汀联合倍他乐克治疗冠心病合并短暂性脑缺血的效果观察[J].中国实用神经疾病杂志,2017,20(3):64~66.
[11] Bondar K Y, Belaya O L, Lazutina O M, et al. Atorvastatin and oxidative stress in coronary heart disease with obesity[J]. Klin Med (Mosk),2012, 90(10): 34~38.